Table 2.
Results showing relationship between baseline characteristics and undetectable viral load among study participants
| Variable | Undetectable viral load, N = 367 | P value | |
|---|---|---|---|
| Yes, n (%) | No, n (%) | ||
| Sex | 0.908 | ||
| Male | 91 (47.4) | 84 (48.0) | |
| Female | 101 (52.6) | 91 (52.0) | |
| Age group | 0.163 | ||
| 0–5 | 133 (69.3) | 136 (77.7) | |
| 6–15 | 49 (25.5) | 34 (19.4) | |
| 15–18 | 10 (5.2) | 5 (2.9) | |
| Timing of ART initiation | 0.065 | ||
| Within 7 days | 103 (53.7) | 77 (44.0) | |
| Beyond 7 days | 89 (46.3) | 98 (56.0) | |
| Mean baseline weight (SD) | 14.4 (14.0) | 11.1 (9.4) | 0.007* |
| Baseline creatinine level | 28.6 (11.2) | 27.6 (12.0) | 0.705 |
| Baseline haemoglobin level | 10.02 (1.9) | 9.57 (1.64) | 0.020* |
| Adherence on ART | 0.001* | ||
| Good adherence (Pill count based) (≥3 consecutive visits) | 38 (19.8) | 72 (41.1) | |
| Inconsistent adherence | 154 (80.2) | 103 (58.9) | |
| Baseline Nutrition status | 0.745 | ||
| Normal limits & mild malnutrition | 102 (53.1) | 90 (51.4) | |
| Moderate & severe malnutrition | 90 (46.9) | 85 (48.6) | |
| TB status | 0.067 | ||
| Positive | 15 (7.8) | 24 (13.7) | |
| Negative | 177 (92.2) | 151 (86.3) | |
| Baseline ART regimen | 0.121 | ||
| Nevirapine based | 66 (34.4) | 77 (44.0) | |
| Efavirenz based | 44 (22.9) | 28 (16.0) | |
| Protease Inhibitor based | 75 (39.1) | 60 (34.3) | |
| Triple RTI | 7 (3.7) | 10 (5.7) | |
| WHO clinical stage | 0.089 | ||
| I & II | 79 (41.2) | 57 (32.6) | |
| III & IV | 113 (58.8) | 118 (67.4) | |
*Significance at p < 0.05